Novo Nordisk
NVO
482 hedge funds and large institutions have $5.6B invested in Novo Nordisk in 2016 Q4 according to their latest regulatory filings, with 73 funds opening new positions, 121 increasing their positions, 212 reducing their positions, and 93 closing their positions.
3.07% less ownership
Funds ownership: 18.56% → 15.48% (-3.1%)
6% less funds holding
Funds holding: 511 → 482 (-29)
22% less first-time investments, than exits
New positions opened: 73 | Existing positions closed: 93
28% less capital invested
Capital invested by funds: $7.76B → $5.6B (-$2.16B)
43% less funds holding in top 10
Funds holding in top 10: 14 → 8 (-6)
43% less repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 212
59% less call options, than puts
Call options by funds: $13.1M | Put options by funds: $31.9M
Top Buyers
Top Sellers
NVO Hedge Fund Activity: Q4 2016 in Review
482 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q4 2016, worth a combined $5.6B — down 28% from $7.76B a quarter earlier.
Sellers outnumbered buyers: 93 funds closed out of NVO and 73 opened new positions — a net loss of 20 holders — while 212 trimmed existing stakes and 121 added.
The largest buyer was Loomis, Sayles & Company, adding an estimated $140M. The largest seller was WCM Investment Management, cutting an estimated $335M.
- 482 institutional investors held Novo Nordisk (NVO) as of Q4 2016, down from 511 in Q3 2016.
- Funds reported $5.6B of Novo Nordisk stock for Q4 2016, down 28% quarter-over-quarter.
- 73 funds opened new Novo Nordisk positions in Q4 2016 and 93 closed out, a net change of -20 holders.
- The largest Novo Nordisk buyer in Q4 2016 was Loomis, Sayles & Company, an estimated $140M added.
- The largest Novo Nordisk seller in Q4 2016 was WCM Investment Management, an estimated $335M sold.
Based on aggregated 13F filings for Q4 2016.